decrease font size
increase font size
change type face
bookmark this page
email this page
print this page

ThePigSite Latest News

Search ThePigSite:
Section:

Use the above box to search this section or the whole site
Tuesday, December 13, 2005
Print This Page

Boehringer Ingelheim Adds Two to Swine Sales Team

MISSOURI - Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces the addition of Chris Beard and Douglas Skartvedt as sales representatives for the company’s swine division. Both have more than 10 years of swine health sales and production experience.

Boehringer Ingelheim UK

Beard most recently served as swine industry specialist for the swine business unit of Pfizer Animal Health. He received his bachelor’s degree in animal science from Purdue University, West Lafayette, Ind. Beard will service customers across the United States. As a BIVI swine division sales representative, he will provide team support in the distribution and sales of the company’s broad portfolio of swine vaccine products.

Skartvedt also served as swine industry specialist and later account manager for the swine business unit of Pfizer Animal Health. He received his bachelor’s degree in animal science from Iowa State University of Ames, Iowa. Skartvedt will serve customers in Minn. and Iowa.

“Doug and Chris’ both have extensive experience and knowledge in the swine industry, which provides a strong foundation for marketing programs directly to veterinarians and producers,” says David Gocken, national sales manager of the BIVI swine division. “We will continue to add sales support and other resources to demonstrate our commitment to the swine industry.”

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation (based in Ridgefield, Conn.), and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2004, Boehringer Ingelheim posted net sales of U.S. $10.2 billion (8.2 billion euro) while spending nearly one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

Source: Boehringer Ingelheim UK - 13th December 2004



Our Newest
Web Site


TheBioenergySite

Thursday 4th December

Search Site